Biogen BIIB

HealthcareMarket cap $35B4 connections

Biogen pioneered multiple sclerosis drug development - its Tecfidera and Tysabri transformed MS treatment. Its Leqembi (lecanemab) is the first drug to meaningfully slow Alzheimer's disease progression, potentially one of the most important pharmaceutical breakthroughs in decades for 55M+ dementia patients globally.

Explore Biogen on the interactive map Relationship timeline Find a path to another company

Partners 4

Strategic partnerships, joint products and alliances

MicrosoftTechnology · $2.8TMicrosoft AI partnership for Alzheimer's drug
AmgenHealthcare · $160BCompeting neurology and MS drug portfolios
Ionis PharmaHealthcare · $8BIonis co-develops neurological drugs with Biogen
Acadia PharmaHealthcare · $4BCompeting CNS neurology drug portfolios

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Biogen's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=BIIB" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Biogen on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.